News | November 14, 2022
Aurobindo Pharma Q2 FY23 revenue down 3.4%
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
Dr. Mandaviya agreed to host the Stop TB Partnership’s 36th Board meeting on March 25-26, 2023 in Varanasi
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
KDAH Indore is a super-speciality, patient-centric, tertiary-care institution located in the Nipaniya area of Indore.
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
The girl child anthem will portray a celebration of a girl child.
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
Subscribe To Our Newsletter & Stay Updated
